Research programme: bispecific antibody drug conjugate - Medilink Therapeutics
Alternative Names: BsAb-ADC; Project 4Latest Information Update: 21 Apr 2022
At a glance
- Originator MediLink Therapeutics
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 21 Apr 2022 Early research in Solid tumours in China (Parenteral) before April 2022 (Medilink Therapeutics pipeline, April 2022)
- 14 Mar 2022 Research programme: bispecific antibody drug conjugate - Medilink Therapeutics is available for licensing as of 14 Mar 2022. http://www.medilinkthera.com/en/a/hezuohuoban/
- 14 Mar 2022 Medilink Therapeutics has patent protection for antibody drug conjugates linker payload technologies